Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | PNMT | P11086 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17133018 | 0.77 | ADRA1A (0.36) | ADRA2APNMTADRA2BADRA2CADRA1A | |
| SCHEMBL12082249 | 0.77 | ADRA1A (0.36) | ADRA2APNMTADRA2BADRA2CADRA1A | |
| SCHEMBL8182953 | 0.76 | ADRA1A (0.33) | ADRA1A | |
| SCHEMBL18371506 | 0.72 | ADRA1A (0.33) | ADRA1AADRA1D | |
| SCHEMBL8182948 | 0.69 | ADRA1A (0.33) | ADRA1A | |
| SCHEMBL10544179 | 0.68 | EGLN1 (0.46) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL24317432 | 0.67 | ADRA2A (0.45) | ADRA2APNMTADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL2944841 | 0.67 | EGLN1 (0.44) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL27419159 | 0.66 | ADRA2A (0.35) | ADRA2APNMTADRA2BADRA2C | |
| SCHEMBL4004122 | 0.66 | ADRA1A (0.39) | ADRA2APNMTADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | ADRA2A 222/4885PNMT 1400/4885ADRA2B 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.